{
    "clinical_study": {
        "@rank": "33599", 
        "acronym": "RINCAL", 
        "arm_group": [
            {
                "arm_group_label": "Conservative Arm- Medical therapy", 
                "arm_group_type": "Other", 
                "description": "Medical therapy"
            }, 
            {
                "arm_group_label": "Invasive Arm-angiogram with PCI or CABG", 
                "arm_group_type": "Other", 
                "description": "same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting)  revascularisation if appropriate"
            }
        ], 
        "brief_summary": {
            "textblock": "For octogenarian patients with NSTEMI (non-ST segment elevation myocardial infarction) an\n      invasive-guided strategy will prove superior to a conservative strategy with respect to a\n      combined endpoint of all cause mortality and non-fatal myocardial infarction."
        }, 
        "brief_title": "Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes", 
        "completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndromes", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  AGE>80 Non-STEMI - characteristic chest pain accompanied by\n\n          -  Typical ischaemic ECG changes\n\n          -  A troponin rise\n\n        Suitable for conservative or invasive strategy\n\n        Exclusion Criteria:\n\n          -  Lack of suitability for whatever clinical reason to be randomised eg dementia,\n             co-morbidity\n\n          -  Acute STEMI\n\n          -  Cardiogenic shock\n\n          -  Platelet count =50 x 109/mm3\n\n          -  Patient life expectancy < 1 year\n\n          -  Known allergies to clopidogrel, aspirin, heparin, stainless steel, IV contrast or\n             stent drug elutant\n\n          -  Recent major GI haemorrhage (within 3 months)\n\n          -  Any previous cerebral bleeding episode\n\n          -  Participation in another investigational drug or device study\n\n          -  Patient unable to give consent\n\n          -  Clinical decision precluding the use of stents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "80 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086019", 
            "org_study_id": "BN-AdB-RINCAL-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Conservative Arm- Medical therapy", 
                "description": "crossover to angiogram only if predefined criteria met", 
                "intervention_name": "Conservative Arm", 
                "intervention_type": "Drug", 
                "other_name": [
                    "low molecular weight heparin,", 
                    "aspirin,", 
                    "clopidogrel,", 
                    "beta blocker (Bisoprolol or equivalent)", 
                    "ACE inhibitor (Ramipril or equivalent)"
                ]
            }, 
            {
                "arm_group_label": "Invasive Arm-angiogram with PCI or CABG", 
                "description": "angiogram with PCI or CABG revascularisation if appropriate", 
                "intervention_name": "Invasive Arm", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin-Converting Enzyme Inhibitors", 
                "Heparin, Low-Molecular-Weight", 
                "Dalteparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Revascularisation, octogenarian,acute coronary syndromes", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "Nicola.Skipper@bsuh.nhs.uk", 
                "last_name": "Nicola Skipper", 
                "phone": "01273 696955", 
                "phone_ext": "7673"
            }, 
            "facility": {
                "address": {
                    "city": "Brighton", 
                    "country": "United Kingdom", 
                    "zip": "BN2 5BE"
                }, 
                "name": "Royal Sussex County Hospital"
            }, 
            "investigator": {
                "last_name": "Adam deBelder, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomised Controlled Trial", 
        "overall_contact": {
            "email": "Nicola.Skipper@bsuh.nhs.uk", 
            "last_name": "Nicola Skipper", 
            "phone": "01273 696955", 
            "phone_ext": "7673"
        }, 
        "overall_contact_backup": {
            "email": "adam.debelder@bsuh.nhs.uk", 
            "last_name": "Adam deBelder, MD", 
            "phone": "01273 696955", 
            "phone_ext": "4897"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Institute for Health Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The cause of death will be adjudicated as being due to cardiovascular causes, non cardiovascular causes, or undetermined causes.\nCardiovascular Death includes sudden cardiac death, death due to acute myocardial infarction, death due to heart failure or cardiogenic shock, death due to stroke or death due to other cardiovascular causes\nNon-Cardiovascular Death is defined as any death not covered by cardiac death or vascular death.\nUndetermined cause of death refers to a death not attributable to one of the above categories of cardiovascular death or to a non-cardiovascular cause.\nN.B For this trial all deaths with undetermined causes will be included in the cardiovascular category.", 
                "measure": "Death", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The ESC/ACC (European Society of Cardiology and the American College of Cardiology) definition of myocardial infarction will be applied, including the special circumstances of same admission myocardial re-infarction, or myocardial infarction peri-PCI.", 
                "measure": "non-fatal myocardial infarction", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086019"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brighton and Sussex University Hospitals NHS Trust", 
            "investigator_full_name": "Adam de Belder", 
            "investigator_title": "Consultant Cardiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Shall be deemed to have occurred at follow-up if any coronary vessel requires or undergoes attempted repeat revascularisation with either balloon angioplasty, stenting, or coronary artery bypass grafting.", 
                "measure": "Unplanned revascularisation", 
                "safety_issue": "No", 
                "time_frame": "1 years"
            }, 
            {
                "description": "A stroke is a loss of neurological function caused by an ischemic or hemorrhagic event with residual symptoms at least 24 hours after onset or leading to death", 
                "measure": "Permanent Stroke", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "BARC (Bleeding Academic Research Consortium) definition", 
                "measure": "Major bleeding", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Worsening renal function is an absolute increase in serum creatinine of \u2265 0.3mg/dl (26.5 umol/l) at any time during hospitalization compared to the valve obtained at admission", 
                "measure": "Deterioration of renal function during hospital admission", 
                "safety_issue": "No", 
                "time_frame": "During index admission"
            }, 
            {
                "description": "CCS (Canadian Cardiovascular Society Classification of angina)  grading of angina", 
                "measure": "Angina symptoms (3 months; 1yr)", 
                "safety_issue": "No", 
                "time_frame": "3 months and 1 year"
            }, 
            {
                "description": "ARC definition of stent Thrombosis", 
                "measure": "Stent thrombosis", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Cardiac and non cardiac mortality", 
                "measure": "All cause mortality", 
                "safety_issue": "No", 
                "time_frame": "2,3 and 4 year"
            }, 
            {
                "description": "ESC/ACC definition ACS/STEMI (Acute coronary syndrome/ST-segment elevation myocardial infarction)", 
                "measure": "Hospital readmission for ACS/STEMI", 
                "safety_issue": "No", 
                "time_frame": "At 3, 6 and 12 months and at 2,3 and 4 years"
            }, 
            {
                "description": "In hospital major complications defined as death, myocardial infarction, stent thrombosis, target restenosis, repeat target- and non-target vessel-related percutaneous coronary intervention, target lesion revascularization, coronary artery bypass surgery and stroke.", 
                "measure": "In-hospital major complications", 
                "safety_issue": "Yes", 
                "time_frame": "At 3, 6 and 12 months and at 2,3 and 4"
            }
        ], 
        "source": "Brighton and Sussex University Hospitals NHS Trust", 
        "sponsors": {
            "collaborator": {
                "agency": "Medtronic Vascular", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Brighton and Sussex University Hospitals NHS Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}